Last reviewed · How we verify
NCT03216733: SORT OUT X
SORT OUT X - Combo Stent Versus ORSIRO Stent
NA trial testing COMBO in Coronary Heart Disease in 3,148 participants. Participants enrolled and being followed up; not accepting new ones.
30 November 2018
Quick facts
| Lead sponsor | Aarhus University Hospital Skejby |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 3,148 |
| Start date | 1 June 2017 |
| Primary completion | 30 November 2018 |
| Estimated completion | 31 December 2028 |
| Sites | 4 locations across Denmark |
Drugs / interventions tested
Conditions studied
- Coronary Heart Disease — all drugs for Coronary Heart Disease →
- Angina Pectoris — all drugs for Angina Pectoris →
- Myocardial Infarction — all drugs for Myocardial Infarction →
Sponsor
Aarhus University Hospital Skejby
Who can join
18 and older, any sex, with Coronary Heart Disease or Angina Pectoris. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the Danish Organisation for randomised trials with clinical outcome (SORT OUT) is to compare the safety and efficacy of the ComboTM stent and Orsiro™ stent in the treatment of unselected patients with ischemic heart disease, using registry detection of clinically driven events.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Rebuilding the Vascular Network: <i>In vivo</i> and <i>in vitro</i> Approaches.
Meng X, Xing Y, Li J, Deng C, et al · · 2021 · cited 36× · PMID 33968926 · DOI 10.3389/fcell.2021.639299 -
Randomized Clinical Comparison of the Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Combo Stent With the Sirolimus-Eluting Orsiro Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT X Trial.
Jakobsen L, Christiansen EH, Freeman P, Kahlert J, et al · · 2021 · cited 30× · PMID 33823606 · DOI 10.1161/circulationaha.120.052766 -
Comparison of Contemporary Drug-eluting Coronary Stents - Is Any Stent Better than the Others?
Parker W, Iqbal J. · · 2020 · cited 12× · PMID 36277668 · DOI 10.17925/hi.2020.14.1.34 -
A Narrative Review of Ultrathin-strut Drug-eluting Stents: The Thinner the Better?
Grundeken MJ, Beijk MA. · · 2021 · cited 9× · PMID 36277831 · DOI 10.17925/hi.2021.15.2.84 -
Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
Jakobsen L, Christiansen EH, Freeman P, Kahlert J, et al · · 2022 · cited 3× · PMID 35384254 · DOI 10.1002/ccd.30175 -
Dual-therapy CD34 antibody-covered sirolimus-eluting COMBO stents versus sirolimus-eluting Orsiro stents in patients treated with percutaneous coronary intervention: the three-year outcomes of the SORT OUT X randomised clinical trial.
Jakobsen L, Christiansen EH, Freeman P, Kahlert J, et al · · 2023 · cited 2× · PMID 37584207 · DOI 10.4244/eij-d-23-00330 -
Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual-therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
Jakobsen L, Christiansen EH, Freeman P, Kahlert J, et al · · 2023 · cited 2× · PMID 36378691 · DOI 10.1002/ccd.30480
Verify or expand the search:
- PubMed search for NCT03216733
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of COMBO
Trials testing the same drug.
- NCT05609097 — PRIME HFrEF: Novel Exercise for Older Patients With Heart Failure With Reduced Ejection Fraction · NA · recruiting
Other recruiting trials for Coronary Heart Disease
Currently open trials in the same condition.
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
- NCT07110415 — Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by · Phase 4 · recruiting
- NCT07451873 — Glycocalyx and Oxidative Stress in Endothelial Function (Part 2) · recruiting
- NCT07118930 — Study of Sivelestat Sodium in OPCABG · Phase 2 · recruiting
Other Aarhus University Hospital Skejby trials
Trials by the same sponsor.
- NCT07422688 — Optical Coherence Tomography in Acute Vessel Evaluation · NA · enrolling by invitation
- NCT05365282 — Association Between Radial Artery Intervention and Development of Neuropathy in the Hand - A Prospective Study · recruiting
- NCT05896904 — Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejec · NA · unknown
- NCT05218694 — Coronary Computed Tomography Angiography For Optimized Invasive Coronary examInation · NA · unknown
- NCT05049421 — The SWEDEGRAFT Right-Heart-Substudy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03216733 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Aarhus University Hospital Skejby
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03216733.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing